MBRX icon

Moleculin Biotech

17 hedge funds and large institutions have $918K invested in Moleculin Biotech in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.

Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
5
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
Vanguard Group
1
Vanguard Group
Pennsylvania
$309K 264,160 +246,202 +1,371%
VKH
2
Virtu KCG Holdings
New York
$274K 233,994 +233,994 New
SM
3
Sabby Management
Florida
$117K 100,000 +100,000 New
Truist Financial
4
Truist Financial
North Carolina
$47K 40,000 +20,000 +100%
Bank of America
5
Bank of America
North Carolina
$29K 25,000
TSS
6
Two Sigma Securities
New York
$28K 24,160 +24,160 New
BlackRock
7
BlackRock
New York
$21K 17,868 +17,868 New
Citadel Advisors
8
Citadel Advisors
Florida
$20K 17,304 +17,304 New
Goldman Sachs
9
Goldman Sachs
New York
$20K 17,509 +17,509 New
Morgan Stanley
10
Morgan Stanley
New York
$13K 10,796 +10,096 +1,442%
Northern Trust
11
Northern Trust
Illinois
$13K 11,155 +11,155 New
WS
12
Wedbush Securities
California
$12K 10,000 +10,000 New
UBS Group
13
UBS Group
Switzerland
$7K 6,537 +4,415 +208%
TRCT
14
Tower Research Capital (TRC)
New York
$4K 3,100 +2,900 +1,450%
AIM
15
Acrospire Investment Management
Illinois
$3K 2,472 +2,472 New
AWMS
16
Advocacy Wealth Management Services
Georgia
$1K 1,000
Citigroup
17
Citigroup
New York
-7,500 Closed
NFG
18
Next Financial Group
Texas
-500 Closed
WA
19
WFG Advisors
Texas
$0 400